Statement of Changes in Beneficial Ownership (4)
January 30 2023 - 05:05PM
Edgar (US Regulatory)
FORM 4
[ ] Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * DeWilde
Michel |
2. Issuer Name and Ticker or Trading
Symbol VBI Vaccines Inc/BC [ VBIV ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
(Last)
(First)
(Middle)
C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3 |
3. Date of Earliest Transaction (MM/DD/YYYY)
1/26/2023
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Option (Right to Buy Common
Shares) |
$0.575 |
1/26/2023 |
|
A |
|
50000 |
|
(1) |
1/26/2033 (2) |
Common Shares |
50000 |
$0 |
50000 |
D |
|
Explanation of
Responses: |
(1) |
The reporting person is a
participant in the Issuer's Incentive Plan (the "Plan"). The board
of directors of the Issuer approved the option grant on January 26,
2023 (the "Grant Date"). The options were granted pursuant to that
certain option agreement entered into by and between the Issuer and
the reporting person, dated January 26, 2023 (the "Option
Agreement"). The options vest and become exercisable in 12 equal
monthly installments beginning on the first day of the month
following the Grant Date, subject to the reporting person's
employment on the relevant vesting date. |
(2) |
The options expire 10 years
from the Grant Date unless terminated sooner in accordance with the
Plan or the Option Agreement. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
DeWilde Michel
C/O VBI VACCINES INC.,
160 SECOND STREET, FLOOR 3
CAMBRIDGE, MA 02142 |
X |
|
|
|
Signatures
|
/s/ Michel DeWilde |
|
1/30/2023 |
**Signature of
Reporting Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 4(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to Jun 2023
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Jun 2022 to Jun 2023